NetScientific PLC’s (LON:NSCI) portfolio company, Vortex BioSciences, has secured a global manufacturing agreement with German firm STRATEC Consumables GmbH to scale up production of its VTX-1 liquid biopsy platform.
The healthcare IP commercialisation firm said STRATEC would assist Vortex in producing a customised chip, a crucial component of its automated platform, as well as assisting the company with scaling up to commercial viability and increasing the product’s prominence in the clinical space as a diagnostic and monitoring tool.
WATCH: 'Pivotal' moment for NetScientific's Glycotest Inc with $10mln financing
Francois Martelet, chief executive of NetScientific and chairman of Vortex, said the partnership would help create a reproducible process that would “allow Vortex's technology to enter the market and readily address demand as it surges”.
NetScientific holds a 66.1% stake in Vortex.